CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Inosine

肌苷 杂质对照品Inosine Impurities

20 个杂质条目20 impurity entries

本页汇总 肌苷 的 20 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 20 impurity reference standards of Inosine. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 肌苷(Inosine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesGenotoxicity and Mutagenicity of Inosine Pranobex
    Journal of veterinary research · 2018 · Tobólska S et al.  ·  PMID 30364916  ·  DOI
  2. 分析方法Analytical MethodsSite-specific quantification of Adenosine-to-Inosine RNA editing by Endonuclease-Mediated qPCR
    Bioorganic & medicinal chemistry · 2024 · Tao WB et al.  ·  PMID 39013280  ·  DOI
  3. 分析方法Analytical MethodsSimultaneous Detection of Adenosine-to-Inosine Editing and N(6)-Methyladenosine at Identical RNA Sites through Deamination-Assisted Reverse Transcription Stalling
    Analytical chemistry · 2024 · Min YH et al.  ·  PMID 38743814  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisConvenient Synthesis of 3-Deazapurine Nucleosides (3-Deazainosine, 3-Deazaadenosine and 3-Deazaguanosine) Using Inosine as a Starting Material
    Current protocols · 2021 · Hinotani N et al.  ·  PMID 34837670  ·  DOI
  • 合成方法SynthesisSynthesis of the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors
    Journal of enzyme inhibition and medicinal chemistry · 2015 · Cholewiński G et al.  ·  PMID 25198892  ·  DOI

肌苷 —— 原料药与杂质对照品Inosine — drug substance & impurities

共 20 个条目(含原料药本体)20 items incl. the drug substance
Inosine Impurity 1 (L-Inosine) structure
1
肌苷杂质1(L-肌苷)Inosine Impurity 1 (L-Inosine)
Inosine Impurity 1 (L-Inosine)
CAS No.21138-24-9
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 2 structure
2
肌苷杂质2Inosine Impurity 2
Inosine Impurity 2
CAS No.146196-07-8
Chemical FormulaC11H13ClN4O4
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 3 structure
3
肌苷杂质3Inosine Impurity 3
Inosine Impurity 3
CAS No.13276-43-2
Chemical FormulaC10H11ClN4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 5 structure
5
肌苷杂质5Inosine Impurity 5
Inosine Impurity 5
CAS No.52678-79-2
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 7 (D-Ribose) structure
7
肌苷杂质7 (D-核糖)Inosine Impurity 7 (D-Ribose)
Inosine Impurity 7 (D-Ribose)
CAS No.50-69-1
Chemical FormulaC5H10O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 8 (α-Inosine) structure
8
肌苷杂质8 (α-肌苷)Inosine Impurity 8 (α-Inosine)
Inosine Impurity 8 (α-Inosine)
CAS No.38183-47-0
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 9 (7-β-Ribofuranosylhypoxanthine) structure
9
肌苷杂质9 (7-β-呋喃核糖基次黄嘌呤)Inosine Impurity 9 (7-β-Ribofuranosylhypoxanthine)
Inosine Impurity 9 (7-β-Ribofuranosylhypoxanthine)
CAS No.10280-01-0
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 10 structure
10
肌苷杂质10Inosine Impurity 10
Inosine Impurity 10
CAS No.686300-20-9
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 11 structure
11
肌苷杂质11Inosine Impurity 11
Inosine Impurity 11
CAS No.18520-77-9
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 12 structure
12
肌苷杂质12Inosine Impurity 12
Inosine Impurity 12
CAS No.18520-78-0
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 13 structure
13
肌苷杂质13Inosine Impurity 13
Inosine Impurity 13
CAS No.18520-88-2
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 14 structure
14
肌苷杂质14Inosine Impurity 14
Inosine Impurity 14
CAS No.55530-22-8
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 15 structure
15
肌苷杂质15Inosine Impurity 15
Inosine Impurity 15
CAS No.24939-03-5
Chemical Formulan(C10H13N4O8P)/n(C9H14N3O8P)
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 16 structure
16
肌苷杂质16Inosine Impurity 16
Inosine Impurity 16
CAS No.54735-61-4
Chemical FormulaC10H12N4O11P22-·2Na+
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 17 Monomer structure
17
肌苷杂质17 单体Inosine Impurity 17 Monomer
Inosine Impurity 17 Monomer
CAS No.131-99-7
Chemical FormulaC10H13N4O8P
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 17 structure
17
肌苷杂质17Inosine Impurity 17
Inosine Impurity 17
CAS No.20813-76-7
Chemical FormulaC10H11N4O8P2-·2Na+·H2O
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 18 structure
18
肌苷杂质18Inosine Impurity 18
Inosine Impurity 18
CAS No.60426-58-6
Chemical FormulaC23H33N5O12
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 19 structure
19
肌苷杂质19Inosine Impurity 19
Inosine Impurity 19
CAS No.60398-20-1
Chemical FormulaC23H33N5O12
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 20 structure
20
肌苷杂质20Inosine Impurity 20
Inosine Impurity 20
CAS No.38925-80-3
Chemical FormulaC26H22Cl2N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Inosine Impurity 42 structure
42
肌苷杂质42Inosine Impurity 42
Inosine Impurity 42
CAS No.126222-04-6
Chemical FormulaC10H14N4O6
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

肌苷 —— 研究文献与合成路线Inosine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 肌苷 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Inosine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis
    Wang H, Mei L, Deng Y, et al. · Nutrition (Burbank, Los Angeles County, Calif.) · 2019 · 被引 114cited 114
  2. Effect of two non-synonymous ecto-5'-nucleotidase variants on the genetic architecture of inosine 5'-monophosphate (IMP) and its degradation products in Japanese Black beef
    Uemoto Y, Ohtake T, Sasago N, et al. · BMC genomics · 2017 · 被引 25cited 25
  3. Inosine, not adenosine, initiates endothelial glycocalyx degradation in cardiac ischemia and hypoxia
    Becker BF, Fischer J, Hartmann H, et al. · Nucleosides, nucleotides & nucleic acids · 2011 · 被引 21cited 21
  4. A review of the kinetics of degradation of inosine monophosphate in some species of fish during chilled storage
    Howgate P · International journal of food science & technology · 2006 · 被引 39cited 39
  5. Degradation of inosine-5'-monophosphate (IMP) in aqueous and in layering chicken muscle fibre systems: Effect of pH and temperature
    Vani ND, Modi VK, Kavitha S, et al. · Lebensmittel-Wissenschaft + [i.e. und] Technologie. Food science + technology. Science + technologie alimentaire · 2006 · 被引 19cited 19
  6. Selective removal of ATP degradation products from food matrices II: Rapid screening of hypoxanthine and inosine by molecularly imprinted matrix solid-phase dispersion for evaluation of fish freshness
    Cela-Pérez MC, Barbosa-Pereira L, Vecino X, et al. · Talanta · 2015 · 被引 13cited 13

合成与制备工艺专利Synthesis & process patents

  1. METHOD FOR MANUFACTURING INOSINE DERIVATIVE
    UEDA TOSHIHIRO, UETAKE KOUICHI · 公开号 WO2010079813WO2010079813 · 2010
  2. INOSINE PRODUCING MICROORGANISM BELONGING TO THE GENUS CORYNEBACTERIUM AND PROCESS OF PRODUCING INOSINE USING THE SAME
    KIM CHUL HA, CHOI JONG SOO, KIM JEONG HWAN, KIM HYOUNG SEOK, et al. · 公开号 US2011003342US2011003342 · 2011
  3. INOSINE PRODUCING MICROORGANISM BELONGING TO THE GENUS CORYNEBACTERIUM AND PROCESS OF PRODUCING INOSINE USING THE SAME
    KIM CHUL HA, CHOI JONG SOO, KIM JEONG HWAN, KIM HYOUNG SEOK, et al. · 公开号 KR20090076614KR20090076614 · 2009
  4. INOSINE PRODUCING MICROORGANISM BELONGING TO THE GENUS CORYNEBACTERIUM AND PROCESS OF PRODUCING INOSINE USING THE SAME
    KIM CHUL HA, CHOI JONG SOO, KIM JEONG HWAN, KIM HYOUNG SEOK, et al. · 公开号 KR20090075548KR20090075548 · 2009
  5. INOSINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
    TORII TAKAYOSH, IZAWA KUNISUKE, JANG DOO OK, CHO DAE HYAN · 公开号 KR20080059591KR20080059591 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

肌苷 杂质谱研究要点Inosine — impurity profiling notes

下面这些是拿到 肌苷 的 20 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 20 impurity entries for Inosine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances